Displaying drugs 7976 - 8000 of 8039 in total
Saredutant
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Endostatin
Investigational
ACY001
Investigational
Pegpleranib
Investigational
Propentofylline
Investigational
APD668
APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also avoid hypoglycemia.
Investigational
Adomiparin
Investigational
Recombinant Bacterial ACE2 Receptors-like Enzyme
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Investigational
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
FavId
FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
Investigational
BG-777
BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Investigational
Quisovalimab
Investigational
Methoxyamine
Investigational
Tin protoporphyrin IX
Investigational
Lanoteplase
Investigational
Sumanirole
Investigational
Omburtamab
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours.[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous...
Investigational
AZX-100
Investigational
Elsiglutide
Investigational
Teprenone
Experimental
LX6171
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
Investigational
Biomed 101
Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Investigational
CSL324
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
Freselestat
Experimental
Investigational
Displaying drugs 7976 - 8000 of 8039 in total